Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

L Liane IF Moura (Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal) A Alessio Malfanti (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) A Ana I Matos (Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal) C Carina Peres (Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal) A Ana Armiñán (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) A Aroa Duro‐Castaño (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) I Inmaculada Conejos‐Sánchez (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) M María Medel (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) S Snežana Đorđević (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) P Paula Carrascosa (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) B Bárbara Carreira (Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal) R Rita C Acúrcio (Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal) H Helena Xavier‐Ferreira (i3S – Instituto de Investigação e Inovação em Saúde Medical Faculty of Porto Universidade do Porto Rua Alfredo Allen, 208 Porto 4200‐135 Portugal) A Alberto Hernández‐Barranco (Microenvironment and Metastasis Laboratory Department of Molecular Oncology Spanish National Cancer Research Center (CNIO) C. de Melchor Fernández Almagro, 3 Madrid 28029 Spain) E Elena Castellano (Microenvironment and Metastasis Laboratory Department of Molecular Oncology Spanish National Cancer Research Center (CNIO) C. de Melchor Fernández Almagro, 3 Madrid 28029 Spain) E Esther Roselló (Department of Pathology Hospital General Universitario de Valencia Av. de les Tres Creus, 2, L'Olivereta Valencia 46014 Spain) J José C. Machado (i3S – Instituto de Investigação e Inovação em Saúde Medical Faculty of Porto Universidade do Porto Rua Alfredo Allen, 208 Porto 4200‐135 Portugal) H Héctor Peinado M María J. Vicent (Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain) H Helena F. Florindo (Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal)

Abstract

AbstractTumor‐associated antigen‐based cancer vaccines suffer from limited clinical success compared to alternative immunotherapies in melanoma, an aggressive skin cancer with an immunosuppressive tumor microenvironment. The anti‐tumor potential of a multivalent nanoconjugate cancer vaccine platform – a cross‐linked star‐shaped polyglutamate carrier (StCl) with marked lymphotropic character conjugated with melanoma‐associated peptide antigens is evaluated through redox‐responsive linkers. The co‐delivery of melanoma‐associated peptide antigens by the nanoconjugate platform induced significant effector immune responses in a mouse melanoma model. The nanoconjugate platform synergized with a PD‐1 inhibitor to revert the immunosuppressive melanoma tumor microenvironment by improving cytotoxic T‐cell infiltration, which prompted a superior anti‐tumor effect with prolonged overall survival without acute organ toxicity. The antigen‐specific anti‐tumor immune response induced by the nanoconjugate platform is also validated in a melanoma patient‐derived xenograft mouse model. A promising, versatile StCl‐based platform is reported for generating off‐the‐shelf multivalent nanoconjugate cancer vaccines for the safe and efficient immunotherapeutic treatment of melanoma.

Article Details

Volume / Issue Vol. 37, Issue 16
Published April 01, 2025
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (20)

L

Liane IF Moura

Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal

A

Alessio Malfanti

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

A

Ana I Matos

Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal

C

Carina Peres

Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal

A

Ana Armiñán

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

A

Aroa Duro‐Castaño

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

I

Inmaculada Conejos‐Sánchez

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

M

María Medel

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

S

Snežana Đorđević

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

P

Paula Carrascosa

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

B

Bárbara Carreira

Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal

R

Rita C Acúrcio

Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal

H

Helena Xavier‐Ferreira

i3S – Instituto de Investigação e Inovação em Saúde Medical Faculty of Porto Universidade do Porto Rua Alfredo Allen, 208 Porto 4200‐135 Portugal

A

Alberto Hernández‐Barranco

Microenvironment and Metastasis Laboratory Department of Molecular Oncology Spanish National Cancer Research Center (CNIO) C. de Melchor Fernández Almagro, 3 Madrid 28029 Spain

E

Elena Castellano

Microenvironment and Metastasis Laboratory Department of Molecular Oncology Spanish National Cancer Research Center (CNIO) C. de Melchor Fernández Almagro, 3 Madrid 28029 Spain

E

Esther Roselló

Department of Pathology Hospital General Universitario de Valencia Av. de les Tres Creus, 2, L'Olivereta Valencia 46014 Spain

J

José C. Machado

i3S – Instituto de Investigação e Inovação em Saúde Medical Faculty of Porto Universidade do Porto Rua Alfredo Allen, 208 Porto 4200‐135 Portugal

H

Héctor Peinado

M

María J. Vicent

Polymer Therapeutics Lab Prince Felipe Research Center (CIPF) C/Eduardo Primo Yúfera 3 Valencia 46012 Spain

H

Helena F. Florindo

Research Institute for Medicines (iMed.ULisboa) Faculty of Pharmacy Universidade de Lisboa Av. Prof. Gama Pinto Lisboa 1649‐003 Portugal